# AMD-Patient-Derived hiPSC-RPE: Gateway for Assessing Novel and Emerging Modulators of Autophagy

> **NIH NIH R21** · UNIVERSITY OF MARYLAND BALTIMORE · 2021 · $231,750

## Abstract

Dr. Sethna: Project Summary
Dr. Sethna is a new investigator seeking to establish himself as an independent researcher in
vision field. He has extensive experience in retinal pigment epithelium (RPE) cell biology,
autophagy, age-related macular degeneration (AMD), and the research methods described in the
grant. Hence, he is the ideal candidate to conduct the study. The project described for the R21
Exploratory grant in the application will be critical for developing rationale treatment options for
AMD patients. AMD is a progressive degenerative disease of the retina and the largest cause of
vision problems in the elderly. Anti-VEGF antibodies are exceptionally efficacious against
neovascular ‘wet’ AMD. Dry AMD occurs in ~90% of the cases, however, as of now there are no
treatment options for preventing or attenuating the disease progression. Dry AMD originates
primarily in the RPE and choroid, secondarily impairing photoreceptor function and integrity. RPE
plays an integral role in photoreceptor survival by canonical and non-canonical autophagy.
Previous studies, including ours, have implicated impaired canonical and non-canonical
autophagy within the RPE in AMD patient samples. Upregulating autophagy flux in RPE, hence,
is a promising yet unexplored avenue for therapeutic development. The discovery and validation
of small molecular therapeutics for elderly people with AMD is the main objective of this project.
We propose to perform a high content screen (HCS) for autophagy flux enhancers using RPE,
the cell type primarily affected by dry AMD. Our exciting preliminary data using small molecule
screen and RPE cell line uncovered three candidate autophagy modulators, and thus support the
feasibility of our proposed studies. Further, we were able to generate and characterize hiPSC-
RPE in our lab. To that end, in Aim 1, we will generate CRISPR-mediated endogenously tagged
LC3 and p62/SQSTM1 and perform a HCS to uncover additional autophagy flux enhancers and
validate them in an orthogonal secondary screen. In Aim 2, we will validate the leads in AMD-
patient-derived human induced pluripotent stem cell-derived RPE (AMD- hiPSC-RPE). Mice do
not recapitulate the AMD phenotype, hence using AMD hiPSC-RPE as the disease relevant
model to validate lead compounds is crucial for treatment options. My long-term goal is
establishing an independent research program with clear translational impact on autophagy and
age-related vision disorders. The project described herein will open up new avenues for basic
and translational research, and will equip me with additional new technical skills, which are
imperative for my future research goals.

## Key facts

- **NIH application ID:** 10283447
- **Project number:** 1R21EY032989-01
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** Zubair M. Ahmed
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $231,750
- **Award type:** 1
- **Project period:** 2021-09-30 → 2023-07-01

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10283447

## Citation

> US National Institutes of Health, RePORTER application 10283447, AMD-Patient-Derived hiPSC-RPE: Gateway for Assessing Novel and Emerging Modulators of Autophagy (1R21EY032989-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10283447. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*